Emily M. Leproust Gets 95,351 Twist Bioscience Shares — Most Still Require Continued Service

The chief executive's performance award was worth an estimated $10.0 million at Monday's close.

Share
Emily M. Leproust Gets 95,351 Twist Bioscience Shares — Most Still Require Continued Service

Emily M. Leproust, chief executive of Twist Bioscience, which makes synthetic DNA and tools for biology research, received 95,351 shares Thursday after satisfying performance goals. An SEC filing filed Monday put 60% of the award under continued-service requirements.

A $10 Million Performance Award

The award had an estimated value of $10.0 million at Monday's close. Leproust's reported direct holdings reached 653,538 shares after the grant, worth approximately $68.6 million at Monday's close.

The grant represents about 15% of her reported post-grant holdings. Meeting the performance targets satisfied one condition of the award; most of the shares still carry a service-based vesting condition.

Sales Preceded The Grant

Leproust's earlier SEC filings recorded sales of 469,459 shares for $75.4 million in the window beginning August 18. Those totals exclude the latest grant and cover nine sale filings across nine trade days, from August 21 through November 3.

The largest of those sales was on September 17: 356,546 shares for $56.3 million, at approximately $157.99 each. On October 1, she sold 46,391 shares for $8.8 million, at approximately $189.04 each.

TWST shares were up about 252% this year as of Friday's close, when they finished at $111.60. Twist generated $376.6 million in fiscal 2025 revenue and served more than 3,800 customers globally, selling synthetic biology products, genetic-sequencing tools and antibody discovery services.

Targets And Staying On

Leproust's earlier equity awards also attached conditions to performance or service. Options granted September 1, 2020, became exercisable on December 19, 2022, after she satisfied their performance goals.

A separate option award vested 25% on October 24, 2020. Its schedule called for another 1/48th of the shares to vest on each monthly anniversary, conditional on continuous service.

The remaining 60% of Thursday's award is scheduled to vest on September 30, 2027, provided Leproust continues serving the company.

Sources

More on Twist Bioscience

All Twist Bioscience (TWST) coverage →